CRSP logo

CRISPR Therapeutics AG (CRSP) Cash From Operations

Annual CFO

-$142.77 M
+$117.60 M+45.17%

December 31, 2024


Summary


Performance

CRSP Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCRSPcash flowmetrics:

Quarterly CFO

-$50.03 M
+$56.88 M+53.20%

December 31, 2024


Summary


Performance

CRSP Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCRSPcash flowmetrics:

TTM CFO

-$142.77 M
+$46.04 M+24.38%

December 31, 2024


Summary


Performance

CRSP TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCRSPcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

CRSP Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+45.2%+47.7%-17.3%
3 y3 years-126.5%+47.7%-17.3%
5 y5 years-351.9%+47.7%-17.3%

CRSP Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-126.5%+71.2%-145.6%+64.8%-126.5%+71.2%
5 y5-year-126.5%+71.2%-106.2%+64.8%-126.0%+71.2%
alltimeall time-126.5%+71.2%-106.2%+64.8%-126.0%+71.2%

CRISPR Therapeutics AG Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$142.77 M(-45.2%)
-$50.03 M(-53.2%)
-$142.77 M(-24.4%)
Sep 2024
-
-$106.91 M(+11.9%)
-$188.82 M(+55.1%)
Jun 2024
-
-$95.58 M(-187.1%)
-$121.76 M(-23.6%)
Mar 2024
-
$109.75 M(-214.2%)
-$159.42 M(-38.8%)
Dec 2023
-$260.38 M(-47.5%)
-$96.07 M(+141.1%)
-$260.38 M(-6.2%)
Sep 2023
-
-$39.86 M(-70.1%)
-$277.63 M(-19.1%)
Jun 2023
-
-$133.25 M(-1614.3%)
-$342.99 M(-2.5%)
Mar 2023
-
$8.80 M(-107.8%)
-$351.70 M(-29.1%)
Dec 2022
-$495.74 M(-192.0%)
-$113.33 M(+7.7%)
-$495.74 M(+5.8%)
Sep 2022
-
-$105.22 M(-25.9%)
-$468.45 M(+5.4%)
Jun 2022
-
-$141.96 M(+5.0%)
-$444.56 M(-188.1%)
Mar 2022
-
-$135.24 M(+57.2%)
$504.40 M(-6.4%)
Dec 2021
$538.97 M(-326.1%)
-$86.04 M(+5.8%)
$538.97 M(-0.9%)
Sep 2021
-
-$81.33 M(-110.1%)
$543.80 M(-1.0%)
Jun 2021
-
$807.00 M(-901.7%)
$549.43 M(-291.5%)
Mar 2021
-
-$100.66 M(+24.0%)
-$286.85 M(+20.3%)
Dec 2020
-$238.37 M
-$81.21 M(+7.3%)
-$238.37 M(+55.0%)
Sep 2020
-
-$75.70 M(+158.5%)
-$153.78 M(-377.9%)
Jun 2020
-
-$29.28 M(-43.9%)
$55.34 M(+14.7%)
DateAnnualQuarterlyTTM
Mar 2020
-
-$52.17 M(-1645.5%)
$48.24 M(-14.9%)
Dec 2019
$56.68 M(-158.9%)
$3.38 M(-97.5%)
$56.68 M(+127.4%)
Sep 2019
-
$133.42 M(-466.7%)
$24.93 M(-119.4%)
Jun 2019
-
-$36.38 M(-16.8%)
-$128.46 M(+9.5%)
Mar 2019
-
-$43.74 M(+54.2%)
-$117.29 M(+21.9%)
Dec 2018
-$96.24 M(+37.3%)
-$28.37 M(+42.1%)
-$96.24 M(+16.4%)
Sep 2018
-
-$19.96 M(-20.8%)
-$82.71 M(+5.2%)
Jun 2018
-
-$25.21 M(+11.1%)
-$78.61 M(+13.3%)
Mar 2018
-
-$22.69 M(+52.9%)
-$69.37 M(-1.0%)
Dec 2017
-$70.09 M(+32.6%)
-$14.84 M(-6.5%)
-$70.09 M(-2.9%)
Sep 2017
-
-$15.87 M(-0.7%)
-$72.22 M(+5.2%)
Jun 2017
-
-$15.97 M(-31.8%)
-$68.63 M(+3.6%)
Mar 2017
-
-$23.41 M(+38.0%)
-$66.26 M(+25.3%)
Dec 2016
-$52.86 M(-188.9%)
-$16.97 M(+38.2%)
-$52.86 M(+47.3%)
Sep 2016
-
-$12.28 M(-9.8%)
-$35.89 M(+52.0%)
Jun 2016
-
-$13.60 M(+35.8%)
-$23.62 M(+135.8%)
Mar 2016
-
-$10.01 M
-$10.01 M
Dec 2015
$59.43 M(-1339.9%)
-
-
Dec 2014
-$4.79 M
-
-

FAQ

  • What is CRISPR Therapeutics AG annual cash flow from operations?
  • What is the all time high annual CFO for CRISPR Therapeutics AG?
  • What is CRISPR Therapeutics AG annual CFO year-on-year change?
  • What is CRISPR Therapeutics AG quarterly cash flow from operations?
  • What is the all time high quarterly CFO for CRISPR Therapeutics AG?
  • What is CRISPR Therapeutics AG quarterly CFO year-on-year change?
  • What is CRISPR Therapeutics AG TTM cash flow from operations?
  • What is the all time high TTM CFO for CRISPR Therapeutics AG?
  • What is CRISPR Therapeutics AG TTM CFO year-on-year change?

What is CRISPR Therapeutics AG annual cash flow from operations?

The current annual CFO of CRSP is -$142.77 M

What is the all time high annual CFO for CRISPR Therapeutics AG?

CRISPR Therapeutics AG all-time high annual cash flow from operations is $538.97 M

What is CRISPR Therapeutics AG annual CFO year-on-year change?

Over the past year, CRSP annual cash flow from operations has changed by +$117.60 M (+45.17%)

What is CRISPR Therapeutics AG quarterly cash flow from operations?

The current quarterly CFO of CRSP is -$50.03 M

What is the all time high quarterly CFO for CRISPR Therapeutics AG?

CRISPR Therapeutics AG all-time high quarterly cash flow from operations is $807.00 M

What is CRISPR Therapeutics AG quarterly CFO year-on-year change?

Over the past year, CRSP quarterly cash flow from operations has changed by +$45.55 M (+47.66%)

What is CRISPR Therapeutics AG TTM cash flow from operations?

The current TTM CFO of CRSP is -$142.77 M

What is the all time high TTM CFO for CRISPR Therapeutics AG?

CRISPR Therapeutics AG all-time high TTM cash flow from operations is $549.43 M

What is CRISPR Therapeutics AG TTM CFO year-on-year change?

Over the past year, CRSP TTM cash flow from operations has changed by -$21.02 M (-17.26%)